Friedlander, Michael
Matulonis, Ursula
Gourley, Charlie
du Bois, Andreas
Vergote, Ignace
Rustin, Gordon
Scott, Clare
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Shirinkin, Vadim
Selle, Frédéric
Fielding, Anitra
Lowe, Elizabeth S.
McMurtry, Emma L.
Spencer, Stuart
Rowe, Philip
Mann, Helen
Parry, David
Ledermann, Jonathan
Article History
Received: 23 April 2018
Revised: 20 August 2018
Accepted: 4 September 2018
First Online: 24 October 2018
Competing interests
: M.F. has received personal fees from Astra Zeneca and MSD. C.G. has received grants and personal fees from AstraZeneca, Tesaro and Nucana, grants from Novartis and Aprea, personal fees from Clovis, Roche and Foundation One, and has a patent issued (PCT/US2012/040805) and patents pending (PCT/GB2013/053202, 1409479.1, 1409476.7 and 1409478.3). A.dB. has received personal fees from Roche, AstraZeneca, Tesaro, Pharmamar and Pfizer. I.V. has received personal fees from GCI Health, Oncoinvent AS, Roche NV, Genmab A/S, Advaxis Inc., Morphotek Inc., F Hoffmann-La Roche Ltd, Cerulean Pharma Inc., Novocure GMBH, AstraZeneca LP, Mateon Therapeutics Inc., Immunogen Inc., Eli Lilly Benelux NV, Amgen Inc., Theradex Europe Limited, Pfizer Inc., Debiopharma International SA, Vifor Pharma België NV, Novartis Pharma AG, MSD Belgium BVBA, Oxigene Inc., Janssen-Cilag, Nektar Therapeutics and Bayer Pharma AG, grants from Amgen and Roche, and support for accommodation and travel from Tesaro, Theradex and Elsevier. G.R. has received personal fees from AstraZeneca and Roche. C.S. has received non-financial support and other from AstraZeneca, non-financial support from Clovis Oncology and Eisai Oncology, and grants and non-financial support from Roche. R.S.-F. has received honoraria from AstraZeneca, Bristol-Myers Squibb, MSD, Novartis and Roche. D.M. has received personal fees from Clovis, Astex Inc., Roche and Tesaro. F.S. has received personal fees from Roche, AstraZeneca, Tesaro and Pharmamar. J.L. has received institutional and personal fees from AstraZeneca; personal fees from Roche, Pfizer, Clovis Oncology and Seattle Genetics; and institutional fees from Merck/MSD. A.F., E.L., E.M., S.S., H.M. and D.P. are employees of AstraZeneca and own stock. P.R. is an employee of AstraZeneca. The remaining authors declare no competing interests.
: The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice and the AstraZeneca policy on bioethics.<sup>21</sup>
: The institutional review boards or independent ethics committees of all investigational sites approved the protocol and all patients provided written, informed consent.
: This study was sponsored by AstraZeneca.